Recruiting studies: Achr Myasthenia Gravis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Phase N/A · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07717281 Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Phase N/A · 23 location(s) · Alexion Pharmaceuticals, Inc. · NCT06967480 Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myast
Phase 3 · 145 location(s) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of M · NCT06463587 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With
Phase 2 · 15 location(s) · argenx · NCT07284420 PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Phase 3 · 13 location(s) · Alexion Pharmaceuticals, Inc. · NCT06607627 ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip
Phase N/A · 18 location(s) · argenx · NCT07294170 Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
Phase 4 · 1 location(s) · University of Colorado, Denver · NCT06860633 Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT06815133 Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
Phase 3 · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05868837 A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Ag
Phase 3 · 125 location(s) · Novartis Pharmaceuticals · NCT06517758 ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Pa
Phase 2 · 2 location(s) · argenx · NCT07673627 Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
Phase N/A · 7 location(s) · AstraZeneca · NCT07247279 Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised My
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT07570589 Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Phase 2 · 40 location(s) · NMD Pharma A/S · NCT06414954

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.